Real-world safety profile of therapy with ibrutinib or acalabrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
作者信息
Hafer Ramsay, Iadevaia Francesco, Rohan Thomas Z, Duong Teresa, Poluch Maria, Keiffer Gina, Li Michael, Ferber Andres, Laurenti Luca, Khoo Alan S, Porcu Pierluigi
机构信息
Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA.
Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University of Sacred Heart, Rome, Italy.
出版信息
Blood Neoplasia. 2024 Dec 28;2(1):100064. doi: 10.1016/j.bneo.2024.100064. eCollection 2025 Feb.
Abstract
摘要
相似文献
1
Real-world safety profile of therapy with ibrutinib or acalabrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Blood Neoplasia. 2024 Dec 28;2(1):100064. doi: 10.1016/j.bneo.2024.100064. eCollection 2025 Feb.
2
Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis.
Ann Hematol. 2024 Nov;103(11):4613-4620. doi: 10.1007/s00277-024-05921-7. Epub 2024 Aug 17.
3
Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib.
Future Oncol. 2024 Jan;20(1):39-53. doi: 10.2217/fon-2023-0436. Epub 2023 Jul 21.
4
A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases.
J Comp Eff Res. 2025 Jun;14(6):e240210. doi: 10.57264/cer-2024-0210. Epub 2025 Apr 22.
5
Cost impact of Bruton's tyrosine kinase inhibitor selection in Medicare patients with chronic lymphocytic leukemia.
J Comp Eff Res. 2025 Jun 23:e250035. doi: 10.57264/cer-2025-0035.
6
Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis.
Clin Ther. 2020 Oct;42(10):1955-1974.e15. doi: 10.1016/j.clinthera.2020.08.017. Epub 2020 Oct 6.
7
Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis.
Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):216-223. doi: 10.1016/j.clml.2020.10.012. Epub 2020 Oct 29.
8
Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia.
Patient Prefer Adherence. 2023 Aug 23;17:2073-2084. doi: 10.2147/PPA.S417180. eCollection 2023.
9
A Comparative Analysis of Cardiovascular Events Associated With Acalabrutinib Versus Ibrutinib in Chronic Lymphocytic Leukemia: Insights From a Global Federated Network.
Pharmacol Res Perspect. 2025 Jun;13(3):e70113. doi: 10.1002/prp2.70113.
10
Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia.
Blood Adv. 2023 Aug 22;7(16):4291-4301. doi: 10.1182/bloodadvances.2023009739.
本文引用的文献
1
Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib.
Future Oncol. 2024 Jan;20(1):39-53. doi: 10.2217/fon-2023-0436. Epub 2023 Jul 21.
2
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial.
Blood. 2023 Aug 24;142(8):687-699. doi: 10.1182/blood.2022018818.
3
A global federated real-world data and analytics platform for research.
JAMIA Open. 2023 May 13;6(2):ooad035. doi: 10.1093/jamiaopen/ooad035. eCollection 2023 Jul.
4
Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia.
Blood Adv. 2023 Aug 22;7(16):4291-4301. doi: 10.1182/bloodadvances.2023009739.
5
Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review.
JAMA. 2023 Mar 21;329(11):918-932. doi: 10.1001/jama.2023.1946.
6
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.
Blood Adv. 2022 Jun 14;6(11):3440-3450. doi: 10.1182/bloodadvances.2021006434.
7
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.
Leukemia. 2022 Apr;36(4):1171-1175. doi: 10.1038/s41375-021-01485-x. Epub 2022 Jan 1.
8
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
J Clin Oncol. 2021 Nov 1;39(31):3441-3452. doi: 10.1200/JCO.21.01210. Epub 2021 Jul 26.
9
Managing toxicities of Bruton tyrosine kinase inhibitors.
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):336-345. doi: 10.1182/hematology.2020000118.
10
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.
Blood. 2020 Apr 9;135(15):1204-1213. doi: 10.1182/blood.2018884940.
Zotero 插件